Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

August 10, 2025

Conditions
Atrial Fibrillation
Interventions
DRUG

Metformin

"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."

BEHAVIORAL

Recommendations for lifestyle modification.

All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.

DEVICE

AliveCor

Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT04625946 - Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation | Biotech Hunter | Biotech Hunter